Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
For #ASBMR2019, we’re excited to host a #TwitterTakeover with, @JavaidKassim, Consultant Rheumatologist and Metabolic Bone Diseases from @UniofOxford and @ndorms! Follow the conversation at #UCBtakeover #fragilityfractures https://t.co/WpEub4GcCb
— UCB News (@ucb_news) 16.09.2019 -
Take a guess at which renewable electricity sources we’re using at UCB: Answer: ✅solar ✅wind ✅hydropower ✅biomass #UCB #Environment https://t.co/CnDlHPgE0e
— UCB News (@ucb_news) 16.09.2019 -
How many of the United Nation’s SDGs are we addressing at UCB? ❏ One ❏ Five ❏ Nine ⬇️ ⬇️ ✅ The right answer: Nine. https://t.co/szNLFXAeXG
— UCB News (@ucb_news) 12.09.2019
